Global Metastatic Melanoma Drug Market Growth 2022-2028
- LP 4855034
- 101 Pages
- February 2022
- Pharmaceuticals
The United States Metastatic Melanoma Drug market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Metastatic Melanoma Drug market, reaching US$ million by the year 2028. As for the Europe Metastatic Melanoma Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Metastatic Melanoma Drug players cover Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Inc., and Morphotek, Inc., etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Metastatic Melanoma Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
AGI-134
ALT-801
ALT-803
AMG-232
Others
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Hospital
Clinic
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Morphotek, Inc.
NewLink Genetics Corporation
Novartis AG
Omeros Corporation
Oncolytics Biotech Inc.
OncoSec Medical Inc.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Pharmis Biofarmaceutica, Lda.
Philogen S.p.A.
Plexxikon Inc.
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Metastatic Melanoma Drug Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Metastatic Melanoma Drug by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Metastatic Melanoma Drug by Country/Region, 2017, 2022 & 2028
2.2 Metastatic Melanoma Drug Segment by Type
2.2.1 AGI-134
2.2.2 ALT-801
2.2.3 ALT-803
2.2.4 AMG-232
2.2.5 Others
2.3 Metastatic Melanoma Drug Sales by Type
2.3.1 Global Metastatic Melanoma Drug Sales Market Share by Type (2017-2022)
2.3.2 Global Metastatic Melanoma Drug Revenue and Market Share by Type (2017-2022)
2.3.3 Global Metastatic Melanoma Drug Sale Price by Type (2017-2022)
2.4 Metastatic Melanoma Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Metastatic Melanoma Drug Sales by Application
2.5.1 Global Metastatic Melanoma Drug Sale Market Share by Application (2017-2022)
2.5.2 Global Metastatic Melanoma Drug Revenue and Market Share by Application (2017-2022)
2.5.3 Global Metastatic Melanoma Drug Sale Price by Application (2017-2022)
3 Global Metastatic Melanoma Drug by Company
3.1 Global Metastatic Melanoma Drug Breakdown Data by Company
3.1.1 Global Metastatic Melanoma Drug Annual Sales by Company (2020-2022)
3.1.2 Global Metastatic Melanoma Drug Sales Market Share by Company (2020-2022)
3.2 Global Metastatic Melanoma Drug Annual Revenue by Company (2020-2022)
3.2.1 Global Metastatic Melanoma Drug Revenue by Company (2020-2022)
3.2.2 Global Metastatic Melanoma Drug Revenue Market Share by Company (2020-2022)
3.3 Global Metastatic Melanoma Drug Sale Price by Company
3.4 Key Manufacturers Metastatic Melanoma Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Metastatic Melanoma Drug Product Location Distribution
3.4.2 Players Metastatic Melanoma Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Metastatic Melanoma Drug by Geographic Region
4.1 World Historic Metastatic Melanoma Drug Market Size by Geographic Region (2017-2022)
4.1.1 Global Metastatic Melanoma Drug Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Metastatic Melanoma Drug Annual Revenue by Geographic Region
4.2 World Historic Metastatic Melanoma Drug Market Size by Country/Region (2017-2022)
4.2.1 Global Metastatic Melanoma Drug Annual Sales by Country/Region (2017-2022)
4.2.2 Global Metastatic Melanoma Drug Annual Revenue by Country/Region
4.3 Americas Metastatic Melanoma Drug Sales Growth
4.4 APAC Metastatic Melanoma Drug Sales Growth
4.5 Europe Metastatic Melanoma Drug Sales Growth
4.6 Middle East & Africa Metastatic Melanoma Drug Sales Growth
5 Americas
5.1 Americas Metastatic Melanoma Drug Sales by Country
5.1.1 Americas Metastatic Melanoma Drug Sales by Country (2017-2022)
5.1.2 Americas Metastatic Melanoma Drug Revenue by Country (2017-2022)
5.2 Americas Metastatic Melanoma Drug Sales by Type
5.3 Americas Metastatic Melanoma Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Metastatic Melanoma Drug Sales by Region
6.1.1 APAC Metastatic Melanoma Drug Sales by Region (2017-2022)
6.1.2 APAC Metastatic Melanoma Drug Revenue by Region (2017-2022)
6.2 APAC Metastatic Melanoma Drug Sales by Type
6.3 APAC Metastatic Melanoma Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Metastatic Melanoma Drug by Country
7.1.1 Europe Metastatic Melanoma Drug Sales by Country (2017-2022)
7.1.2 Europe Metastatic Melanoma Drug Revenue by Country (2017-2022)
7.2 Europe Metastatic Melanoma Drug Sales by Type
7.3 Europe Metastatic Melanoma Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Metastatic Melanoma Drug by Country
8.1.1 Middle East & Africa Metastatic Melanoma Drug Sales by Country (2017-2022)
8.1.2 Middle East & Africa Metastatic Melanoma Drug Revenue by Country (2017-2022)
8.2 Middle East & Africa Metastatic Melanoma Drug Sales by Type
8.3 Middle East & Africa Metastatic Melanoma Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Metastatic Melanoma Drug
10.3 Manufacturing Process Analysis of Metastatic Melanoma Drug
10.4 Industry Chain Structure of Metastatic Melanoma Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Metastatic Melanoma Drug Distributors
11.3 Metastatic Melanoma Drug Customer
12 World Forecast Review for Metastatic Melanoma Drug by Geographic Region
12.1 Global Metastatic Melanoma Drug Market Size Forecast by Region
12.1.1 Global Metastatic Melanoma Drug Forecast by Region (2023-2028)
12.1.2 Global Metastatic Melanoma Drug Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Metastatic Melanoma Drug Forecast by Type
12.7 Global Metastatic Melanoma Drug Forecast by Application
13 Key Players Analysis
13.1 Merck & Co., Inc.
13.1.1 Merck & Co., Inc. Company Information
13.1.2 Merck & Co., Inc. Metastatic Melanoma Drug Product Offered
13.1.3 Merck & Co., Inc. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Merck & Co., Inc. Main Business Overview
13.1.5 Merck & Co., Inc. Latest Developments
13.2 Merck KGaA
13.2.1 Merck KGaA Company Information
13.2.2 Merck KGaA Metastatic Melanoma Drug Product Offered
13.2.3 Merck KGaA Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Merck KGaA Main Business Overview
13.2.5 Merck KGaA Latest Developments
13.3 Millennium Pharmaceuticals, Inc.
13.3.1 Millennium Pharmaceuticals, Inc. Company Information
13.3.2 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Product Offered
13.3.3 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Millennium Pharmaceuticals, Inc. Main Business Overview
13.3.5 Millennium Pharmaceuticals, Inc. Latest Developments
13.4 Morphotek, Inc.
13.4.1 Morphotek, Inc. Company Information
13.4.2 Morphotek, Inc. Metastatic Melanoma Drug Product Offered
13.4.3 Morphotek, Inc. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Morphotek, Inc. Main Business Overview
13.4.5 Morphotek, Inc. Latest Developments
13.5 NewLink Genetics Corporation
13.5.1 NewLink Genetics Corporation Company Information
13.5.2 NewLink Genetics Corporation Metastatic Melanoma Drug Product Offered
13.5.3 NewLink Genetics Corporation Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 NewLink Genetics Corporation Main Business Overview
13.5.5 NewLink Genetics Corporation Latest Developments
13.6 Novartis AG
13.6.1 Novartis AG Company Information
13.6.2 Novartis AG Metastatic Melanoma Drug Product Offered
13.6.3 Novartis AG Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Novartis AG Main Business Overview
13.6.5 Novartis AG Latest Developments
13.7 Omeros Corporation
13.7.1 Omeros Corporation Company Information
13.7.2 Omeros Corporation Metastatic Melanoma Drug Product Offered
13.7.3 Omeros Corporation Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Omeros Corporation Main Business Overview
13.7.5 Omeros Corporation Latest Developments
13.8 Oncolytics Biotech Inc.
13.8.1 Oncolytics Biotech Inc. Company Information
13.8.2 Oncolytics Biotech Inc. Metastatic Melanoma Drug Product Offered
13.8.3 Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Oncolytics Biotech Inc. Main Business Overview
13.8.5 Oncolytics Biotech Inc. Latest Developments
13.9 OncoSec Medical Inc.
13.9.1 OncoSec Medical Inc. Company Information
13.9.2 OncoSec Medical Inc. Metastatic Melanoma Drug Product Offered
13.9.3 OncoSec Medical Inc. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 OncoSec Medical Inc. Main Business Overview
13.9.5 OncoSec Medical Inc. Latest Developments
13.10 Ono Pharmaceutical Co., Ltd.
13.10.1 Ono Pharmaceutical Co., Ltd. Company Information
13.10.2 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Product Offered
13.10.3 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Ono Pharmaceutical Co., Ltd. Main Business Overview
13.10.5 Ono Pharmaceutical Co., Ltd. Latest Developments
13.11 Pfizer Inc.
13.11.1 Pfizer Inc. Company Information
13.11.2 Pfizer Inc. Metastatic Melanoma Drug Product Offered
13.11.3 Pfizer Inc. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Pfizer Inc. Main Business Overview
13.11.5 Pfizer Inc. Latest Developments
13.12 Pharmis Biofarmaceutica, Lda.
13.12.1 Pharmis Biofarmaceutica, Lda. Company Information
13.12.2 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Product Offered
13.12.3 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Pharmis Biofarmaceutica, Lda. Main Business Overview
13.12.5 Pharmis Biofarmaceutica, Lda. Latest Developments
13.13 Philogen S.p.A.
13.13.1 Philogen S.p.A. Company Information
13.13.2 Philogen S.p.A. Metastatic Melanoma Drug Product Offered
13.13.3 Philogen S.p.A. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Philogen S.p.A. Main Business Overview
13.13.5 Philogen S.p.A. Latest Developments
13.14 Plexxikon Inc.
13.14.1 Plexxikon Inc. Company Information
13.14.2 Plexxikon Inc. Metastatic Melanoma Drug Product Offered
13.14.3 Plexxikon Inc. Metastatic Melanoma Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Plexxikon Inc. Main Business Overview
13.14.5 Plexxikon Inc. Latest Developments
14 Research Findings and Conclusion
Table 1. Metastatic Melanoma Drug Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Metastatic Melanoma Drug Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of AGI-134
Table 4. Major Players of ALT-801
Table 5. Major Players of ALT-803
Table 6. Major Players of AMG-232
Table 7. Major Players of Others
Table 8. Global Metastatic Melanoma Drug Sales by Type (2017-2022) & (K Pcs)
Table 9. Global Metastatic Melanoma Drug Sales Market Share by Type (2017-2022)
Table 10. Global Metastatic Melanoma Drug Revenue by Type (2017-2022) & ($ million)
Table 11. Global Metastatic Melanoma Drug Revenue Market Share by Type (2017-2022)
Table 12. Global Metastatic Melanoma Drug Sale Price by Type (2017-2022) & (USD/Pcs)
Table 13. Global Metastatic Melanoma Drug Sales by Application (2017-2022) & (K Pcs)
Table 14. Global Metastatic Melanoma Drug Sales Market Share by Application (2017-2022)
Table 15. Global Metastatic Melanoma Drug Revenue by Application (2017-2022)
Table 16. Global Metastatic Melanoma Drug Revenue Market Share by Application (2017-2022)
Table 17. Global Metastatic Melanoma Drug Sale Price by Application (2017-2022) & (USD/Pcs)
Table 18. Global Metastatic Melanoma Drug Sales by Company (2020-2022) & (K Pcs)
Table 19. Global Metastatic Melanoma Drug Sales Market Share by Company (2020-2022)
Table 20. Global Metastatic Melanoma Drug Revenue by Company (2020-2022) ($ Millions)
Table 21. Global Metastatic Melanoma Drug Revenue Market Share by Company (2020-2022)
Table 22. Global Metastatic Melanoma Drug Sale Price by Company (2020-2022) & (USD/Pcs)
Table 23. Key Manufacturers Metastatic Melanoma Drug Producing Area Distribution and Sales Area
Table 24. Players Metastatic Melanoma Drug Products Offered
Table 25. Metastatic Melanoma Drug Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Metastatic Melanoma Drug Sales by Geographic Region (2017-2022) & (K Pcs)
Table 29. Global Metastatic Melanoma Drug Sales Market Share Geographic Region (2017-2022)
Table 30. Global Metastatic Melanoma Drug Revenue by Geographic Region (2017-2022) & ($ millions)
Table 31. Global Metastatic Melanoma Drug Revenue Market Share by Geographic Region (2017-2022)
Table 32. Global Metastatic Melanoma Drug Sales by Country/Region (2017-2022) & (K Pcs)
Table 33. Global Metastatic Melanoma Drug Sales Market Share by Country/Region (2017-2022)
Table 34. Global Metastatic Melanoma Drug Revenue by Country/Region (2017-2022) & ($ millions)
Table 35. Global Metastatic Melanoma Drug Revenue Market Share by Country/Region (2017-2022)
Table 36. Americas Metastatic Melanoma Drug Sales by Country (2017-2022) & (K Pcs)
Table 37. Americas Metastatic Melanoma Drug Sales Market Share by Country (2017-2022)
Table 38. Americas Metastatic Melanoma Drug Revenue by Country (2017-2022) & ($ Millions)
Table 39. Americas Metastatic Melanoma Drug Revenue Market Share by Country (2017-2022)
Table 40. Americas Metastatic Melanoma Drug Sales by Type (2017-2022) & (K Pcs)
Table 41. Americas Metastatic Melanoma Drug Sales Market Share by Type (2017-2022)
Table 42. Americas Metastatic Melanoma Drug Sales by Application (2017-2022) & (K Pcs)
Table 43. Americas Metastatic Melanoma Drug Sales Market Share by Application (2017-2022)
Table 44. APAC Metastatic Melanoma Drug Sales by Region (2017-2022) & (K Pcs)
Table 45. APAC Metastatic Melanoma Drug Sales Market Share by Region (2017-2022)
Table 46. APAC Metastatic Melanoma Drug Revenue by Region (2017-2022) & ($ Millions)
Table 47. APAC Metastatic Melanoma Drug Revenue Market Share by Region (2017-2022)
Table 48. APAC Metastatic Melanoma Drug Sales by Type (2017-2022) & (K Pcs)
Table 49. APAC Metastatic Melanoma Drug Sales Market Share by Type (2017-2022)
Table 50. APAC Metastatic Melanoma Drug Sales by Application (2017-2022) & (K Pcs)
Table 51. APAC Metastatic Melanoma Drug Sales Market Share by Application (2017-2022)
Table 52. Europe Metastatic Melanoma Drug Sales by Country (2017-2022) & (K Pcs)
Table 53. Europe Metastatic Melanoma Drug Sales Market Share by Country (2017-2022)
Table 54. Europe Metastatic Melanoma Drug Revenue by Country (2017-2022) & ($ Millions)
Table 55. Europe Metastatic Melanoma Drug Revenue Market Share by Country (2017-2022)
Table 56. Europe Metastatic Melanoma Drug Sales by Type (2017-2022) & (K Pcs)
Table 57. Europe Metastatic Melanoma Drug Sales Market Share by Type (2017-2022)
Table 58. Europe Metastatic Melanoma Drug Sales by Application (2017-2022) & (K Pcs)
Table 59. Europe Metastatic Melanoma Drug Sales Market Share by Application (2017-2022)
Table 60. Middle East & Africa Metastatic Melanoma Drug Sales by Country (2017-2022) & (K Pcs)
Table 61. Middle East & Africa Metastatic Melanoma Drug Sales Market Share by Country (2017-2022)
Table 62. Middle East & Africa Metastatic Melanoma Drug Revenue by Country (2017-2022) & ($ Millions)
Table 63. Middle East & Africa Metastatic Melanoma Drug Revenue Market Share by Country (2017-2022)
Table 64. Middle East & Africa Metastatic Melanoma Drug Sales by Type (2017-2022) & (K Pcs)
Table 65. Middle East & Africa Metastatic Melanoma Drug Sales Market Share by Type (2017-2022)
Table 66. Middle East & Africa Metastatic Melanoma Drug Sales by Application (2017-2022) & (K Pcs)
Table 67. Middle East & Africa Metastatic Melanoma Drug Sales Market Share by Application (2017-2022)
Table 68. Key Market Drivers & Growth Opportunities of Metastatic Melanoma Drug
Table 69. Key Market Challenges & Risks of Metastatic Melanoma Drug
Table 70. Key Industry Trends of Metastatic Melanoma Drug
Table 71. Metastatic Melanoma Drug Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. Metastatic Melanoma Drug Distributors List
Table 74. Metastatic Melanoma Drug Customer List
Table 75. Global Metastatic Melanoma Drug Sales Forecast by Region (2023-2028) & (K Pcs)
Table 76. Global Metastatic Melanoma Drug Sales Market Forecast by Region
Table 77. Global Metastatic Melanoma Drug Revenue Forecast by Region (2023-2028) & ($ millions)
Table 78. Global Metastatic Melanoma Drug Revenue Market Share Forecast by Region (2023-2028)
Table 79. Americas Metastatic Melanoma Drug Sales Forecast by Country (2023-2028) & (K Pcs)
Table 80. Americas Metastatic Melanoma Drug Revenue Forecast by Country (2023-2028) & ($ millions)
Table 81. APAC Metastatic Melanoma Drug Sales Forecast by Region (2023-2028) & (K Pcs)
Table 82. APAC Metastatic Melanoma Drug Revenue Forecast by Region (2023-2028) & ($ millions)
Table 83. Europe Metastatic Melanoma Drug Sales Forecast by Country (2023-2028) & (K Pcs)
Table 84. Europe Metastatic Melanoma Drug Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Middle East & Africa Metastatic Melanoma Drug Sales Forecast by Country (2023-2028) & (K Pcs)
Table 86. Middle East & Africa Metastatic Melanoma Drug Revenue Forecast by Country (2023-2028) & ($ millions)
Table 87. Global Metastatic Melanoma Drug Sales Forecast by Type (2023-2028) & (K Pcs)
Table 88. Global Metastatic Melanoma Drug Sales Market Share Forecast by Type (2023-2028)
Table 89. Global Metastatic Melanoma Drug Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 90. Global Metastatic Melanoma Drug Revenue Market Share Forecast by Type (2023-2028)
Table 91. Global Metastatic Melanoma Drug Sales Forecast by Application (2023-2028) & (K Pcs)
Table 92. Global Metastatic Melanoma Drug Sales Market Share Forecast by Application (2023-2028)
Table 93. Global Metastatic Melanoma Drug Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 94. Global Metastatic Melanoma Drug Revenue Market Share Forecast by Application (2023-2028)
Table 95. Merck & Co., Inc. Basic Information, Metastatic Melanoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. Merck & Co., Inc. Metastatic Melanoma Drug Product Offered
Table 97. Merck & Co., Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 98. Merck & Co., Inc. Main Business
Table 99. Merck & Co., Inc. Latest Developments
Table 100. Merck KGaA Basic Information, Metastatic Melanoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 101. Merck KGaA Metastatic Melanoma Drug Product Offered
Table 102. Merck KGaA Metastatic Melanoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 103. Merck KGaA Main Business
Table 104. Merck KGaA Latest Developments
Table 105. Millennium Pharmaceuticals, Inc. Basic Information, Metastatic Melanoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 106. Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Product Offered
Table 107. Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 108. Millennium Pharmaceuticals, Inc. Main Business
Table 109. Millennium Pharmaceuticals, Inc. Latest Developments
Table 110. Morphotek, Inc. Basic Information, Metastatic Melanoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 111. Morphotek, Inc. Metastatic Melanoma Drug Product Offered
Table 112. Morphotek, Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 113. Morphotek, Inc. Main Business
Table 114. Morphotek, Inc. Latest Developments
Table 115. NewLink Genetics Corporation Basic Information, Metastatic Melanoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 116. NewLink Genetics Corporation Metastatic Melanoma Drug Product Offered
Table 117. NewLink Genetics Corporation Metastatic Melanoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 118. NewLink Genetics Corporation Main Business
Table 119. NewLink Genetics Corporation Latest Developments
Table 120. Novartis AG Basic Information, Metastatic Melanoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 121. Novartis AG Metastatic Melanoma Drug Product Offered
Table 122. Novartis AG Metastatic Melanoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 123. Novartis AG Main Business
Table 124. Novartis AG Latest Developments
Table 125. Omeros Corporation Basic Information, Metastatic Melanoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 126. Omeros Corporation Metastatic Melanoma Drug Product Offered
Table 127. Omeros Corporation Metastatic Melanoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 128. Omeros Corporation Main Business
Table 129. Omeros Corporation Latest Developments
Table 130. Oncolytics Biotech Inc. Basic Information, Metastatic Melanoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 131. Oncolytics Biotech Inc. Metastatic Melanoma Drug Product Offered
Table 132. Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 133. Oncolytics Biotech Inc. Main Business
Table 134. Oncolytics Biotech Inc. Latest Developments
Table 135. OncoSec Medical Inc. Basic Information, Metastatic Melanoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 136. OncoSec Medical Inc. Metastatic Melanoma Drug Product Offered
Table 137. OncoSec Medical Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 138. OncoSec Medical Inc. Main Business
Table 139. OncoSec Medical Inc. Latest Developments
Table 140. Ono Pharmaceutical Co., Ltd. Basic Information, Metastatic Melanoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 141. Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Product Offered
Table 142. Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 143. Ono Pharmaceutical Co., Ltd. Main Business
Table 144. Ono Pharmaceutical Co., Ltd. Latest Developments
Table 145. Pfizer Inc. Basic Information, Metastatic Melanoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 146. Pfizer Inc. Metastatic Melanoma Drug Product Offered
Table 147. Pfizer Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 148. Pfizer Inc. Main Business
Table 149. Pfizer Inc. Latest Developments
Table 150. Pharmis Biofarmaceutica, Lda. Basic Information, Metastatic Melanoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 151. Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Product Offered
Table 152. Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 153. Pharmis Biofarmaceutica, Lda. Main Business
Table 154. Pharmis Biofarmaceutica, Lda. Latest Developments
Table 155. Philogen S.p.A. Basic Information, Metastatic Melanoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 156. Philogen S.p.A. Metastatic Melanoma Drug Product Offered
Table 157. Philogen S.p.A. Metastatic Melanoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 158. Philogen S.p.A. Main Business
Table 159. Philogen S.p.A. Latest Developments
Table 160. Plexxikon Inc. Basic Information, Metastatic Melanoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 161. Plexxikon Inc. Metastatic Melanoma Drug Product Offered
Table 162. Plexxikon Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 163. Plexxikon Inc. Main Business
Table 164. Plexxikon Inc. Latest Developments
List of Figures
Figure 1. Picture of Metastatic Melanoma Drug
Figure 2. Metastatic Melanoma Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Metastatic Melanoma Drug Sales Growth Rate 2017-2028 (K Pcs)
Figure 7. Global Metastatic Melanoma Drug Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Metastatic Melanoma Drug Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of AGI-134
Figure 10. Product Picture of ALT-801
Figure 11. Product Picture of ALT-803
Figure 12. Product Picture of AMG-232
Figure 13. Product Picture of Others
Figure 14. Global Metastatic Melanoma Drug Sales Market Share by Type in 2021
Figure 15. Global Metastatic Melanoma Drug Revenue Market Share by Type (2017-2022)
Figure 16. Metastatic Melanoma Drug Consumed in Hospital
Figure 17. Global Metastatic Melanoma Drug Market: Hospital (2017-2022) & (K Pcs)
Figure 18. Metastatic Melanoma Drug Consumed in Clinic
Figure 19. Global Metastatic Melanoma Drug Market: Clinic (2017-2022) & (K Pcs)
Figure 20. Metastatic Melanoma Drug Consumed in Others
Figure 21. Global Metastatic Melanoma Drug Market: Others (2017-2022) & (K Pcs)
Figure 22. Global Metastatic Melanoma Drug Sales Market Share by Application (2017-2022)
Figure 23. Global Metastatic Melanoma Drug Revenue Market Share by Application in 2021
Figure 24. Metastatic Melanoma Drug Revenue Market by Company in 2021 ($ Million)
Figure 25. Global Metastatic Melanoma Drug Revenue Market Share by Company in 2021
Figure 26. Global Metastatic Melanoma Drug Sales Market Share by Geographic Region (2017-2022)
Figure 27. Global Metastatic Melanoma Drug Revenue Market Share by Geographic Region in 2021
Figure 28. Global Metastatic Melanoma Drug Sales Market Share by Region (2017-2022)
Figure 29. Global Metastatic Melanoma Drug Revenue Market Share by Country/Region in 2021
Figure 30. Americas Metastatic Melanoma Drug Sales 2017-2022 (K Pcs)
Figure 31. Americas Metastatic Melanoma Drug Revenue 2017-2022 ($ Millions)
Figure 32. APAC Metastatic Melanoma Drug Sales 2017-2022 (K Pcs)
Figure 33. APAC Metastatic Melanoma Drug Revenue 2017-2022 ($ Millions)
Figure 34. Europe Metastatic Melanoma Drug Sales 2017-2022 (K Pcs)
Figure 35. Europe Metastatic Melanoma Drug Revenue 2017-2022 ($ Millions)
Figure 36. Middle East & Africa Metastatic Melanoma Drug Sales 2017-2022 (K Pcs)
Figure 37. Middle East & Africa Metastatic Melanoma Drug Revenue 2017-2022 ($ Millions)
Figure 38. Americas Metastatic Melanoma Drug Sales Market Share by Country in 2021
Figure 39. Americas Metastatic Melanoma Drug Revenue Market Share by Country in 2021
Figure 40. United States Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 41. Canada Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 42. Mexico Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 43. Brazil Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 44. APAC Metastatic Melanoma Drug Sales Market Share by Region in 2021
Figure 45. APAC Metastatic Melanoma Drug Revenue Market Share by Regions in 2021
Figure 46. China Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 47. Japan Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 48. South Korea Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 49. Southeast Asia Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 50. India Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 51. Australia Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 52. Europe Metastatic Melanoma Drug Sales Market Share by Country in 2021
Figure 53. Europe Metastatic Melanoma Drug Revenue Market Share by Country in 2021
Figure 54. Germany Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 55. France Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 56. UK Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 57. Italy Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 58. Russia Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 59. Middle East & Africa Metastatic Melanoma Drug Sales Market Share by Country in 2021
Figure 60. Middle East & Africa Metastatic Melanoma Drug Revenue Market Share by Country in 2021
Figure 61. Egypt Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 62. South Africa Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 63. Israel Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 64. Turkey Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 65. GCC Country Metastatic Melanoma Drug Revenue Growth 2017-2022 ($ Millions)
Figure 66. Manufacturing Cost Structure Analysis of Metastatic Melanoma Drug in 2021
Figure 67. Manufacturing Process Analysis of Metastatic Melanoma Drug
Figure 68. Industry Chain Structure of Metastatic Melanoma Drug
Figure 69. Channels of Distribution
Figure 70. Distributors Profiles
Similar Reports
The United States pneumococcal & meningococcal vaccines market is set to surpass US$ 7.5 Million by the year end of 2025. “United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025” presents an in–depth assessment of the United States pneumococcal & meningococcal vaccines market dynamics, opportunitie...
- Publish Date: June 24, 2019
- $1050
The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscap...
- Publish Date: February 18, 2019
- $1290
The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘’Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the m...
- Publish Date: December 11, 2018
- $1390
